Following their toplining in June, the keenly awaited full results of the pivotal HELIOS-B trial of Alnylam Pharmaceuticals Inc.’s Amvuttra in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) have turned out to be something of a disappointment.
Key Takeaways
- Full data from the HELIOS-B trial of Alnylam’s Amvuttra in transthyretin amyloidosis with cardiomyopathy look weaker than data on Pfizer’s Vyndamax and BridgeBio’s acoramidis.
The data, presented at the annual congress of the European Society of Cardiology in London on 30 August, suggest that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?